Zhipu AI Stock Jumps on Report of Custom AI Chip Development Plans 
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
SK Hynix’s $28B U.S. IPO Draws Strong Demand as AI Chip Boom Fuels Investor Interest 
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices 
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns 
Netflix, Disney, YouTube Eye FIFA World Cup TV Rights in Multi-Billion Dollar Battle 
SK Hynix’s $28 Billion U.S. Share Sale Draws Massive Demand Amid AI Chip Boom 
(4) - EconoTimes)
DUBLIN, IRELAND, May 04, 2018 -- Horizon Pharma plc (NASDAQ:HZNP) today announced that the compensation committee of its board of directors approved the grant on May 1, 2018 of inducement restricted stock units for an aggregate of 228,305 ordinary shares to 30 new employees.
Certain of the restricted stock units vest over four years, with 25 percent of the shares vesting on each anniversary of the applicable vesting commencement date, and certain of the restricted stock units vest over three years, with 1/3 of the shares vesting on each anniversary of the applicable vesting commencement date. All awards are subject to the new employee's continued service relationship with the Company. Each restricted stock unit also is subject to the terms and conditions of the Company's 2014 Equity Incentive Plan and the restricted stock unit agreement pursuant to which the restricted stock unit was granted.
The restricted stock units were granted as inducements material to the new employees entering into employment with Horizon Pharma in accordance with NASDAQ Listing Rule 5635(c)(4).
About Horizon Pharma plc
Horizon Pharma plc is focused on researching, developing and commercializing innovative medicines that address unmet treatment needs for rare and rheumatic diseases. By fostering a growing pipeline of medicines in development and exploring all potential uses for currently marketed medicines, we strive to make a powerful difference for patients, their caregivers and physicians. For us, it’s personal: by living up to our own potential, we are helping others live up to theirs. For more information, please visit www.horizonpharma.com. Follow @HZNPplc on Twitter, like us on Facebook or explore career opportunities on LinkedIn.
Contacts:
Tina Ventura
Senior Vice President, Investor Relations
[email protected]
Ruth Venning
Executive Director, Investor Relations
[email protected]
U.S. Media Contact:
Geoffrey Curtis
Senior Vice President, Corporate Affairs and Chief Communications Officer
[email protected]
Ireland Media Contact:
Ray Gordon
Gordon MRM
[email protected]
